DAXX and gastrointestinal stromal tumor: In gastrointestinal stromal tumors (GISTs), only 3.3% of cases showed loss of DAXX immunoexpression and telomere dysregulation (defined as telomerase reverse transcriptase (TERT) promoter mutations or loss of either ATRX or DAXX expression) was frequently seen in GISTs of non-gastric origin but did not statistically correlate with any clinicopathological characteristics, DFS or OS [38].